| Antimicrobial | Overall expected coverage (% susceptible of all pathogens) |
||
|---|---|---|---|
| Germany | Spain | USA | |
| Tigecycline | 87.5 | 85.1 | 90.6 |
| Vancomycin | 66.9 | 59.5 | 73.4 |
| Linezolid | 66.9 | 59.5 | 74.4 |
| Levofloxacin | 88.3 | 84.6 | 75.7 |
| Piperacillin/tazobactam | 96.0 | 90.0 | 75.6 |
| Imipenem | 95.8 | 92.1 | 74.1 |
| Cefazolin | 73.2 | 66.2 | 60.1 |
| Ceftriaxone | 80.2 | 74.3 | 64.0 |
| Vancomycin & Piperacillin/tazobactam | 98.2 | 95.8 | 95.7 |
| Vancomycin & Levofloxacin | 95.5 | 93.1 | 93.8 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.